If what you envision actually takes place, Afrezza would lose the additional royalty cash flow from a potential FDA approved Tyvaso DPI. I doubt that "the new Mannkind" could continue as a going concern, for long, without a huge lump sum payment from UTHR for Tyvaso DPI. Rather, I could see UTHR keeping Afrezza, and building its market organically. UTHR could be very helpful in further developing Afrezza's market, if they were willing to take the risk in an entirely new market. JMHO.
P.S. If another insulin mfg. co. bought Afrezza, they would probably try
to kill it. JMHO.